Ocular Carteolol: A Review of its Use in the Management of Glaucoma and Ocular Hypertension

Authors: Henness, Sheridan; Tracy Swainston Harrison,; Keating, Gillian M.

Source: Drugs & Aging, Volume 24, Number 6, 2007 , pp. 509-528(20)

Buy & download fulltext article:

Price: $62.95 plus tax (Refund Policy)

Abstract:

Ocular carteolol (Mikelan^®, Teoptic^®, Ocupress^®) is a nonselective β-adrenoceptor antagonist with intrinsic sympathomimetic activity (ISA). Ocular carteolol effectively reduces intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension (OH). Twice-daily administration of standard carteolol has generally similar IOP-lowering efficacy to other ocular β-adrenoceptor antagonists such as timolol, betaxolol and metipranolol in patients with OAG or OH. In addition, long-term treatment with carteolol has similar efficacy to timolol and betaxolol in terms of reducing IOP and maintaining visual fields in patients with newly diagnosed primary OAG (POAG). The new long-acting formulation of once-daily carteolol has equivalent efficacy to the standard formulation of carteolol administered twice daily in patients with OAG or OH. Both the standard and long-acting formulations of ocular carteolol are generally well tolerated in terms of topical adverse effects involving the eyes or systemic adverse effects involving the cardiovascular system. Thus, twice-daily carteolol is a well established option in the treatment of glaucoma and OH, and the new once-daily formulation of long-acting carteolol offers similar efficacy and tolerability with a potential for improved patient adherence.

Keywords: Adis Drug Evaluations; Carteolol; Glaucoma; Ocular hypertension

Document Type: Research article

Affiliations: 1: Wolters Kluwer Health | Adis, Auckland, New Zealand, an editorial office of Wolters Kluwer Health, Conshohocken, Pennsylvania, USA

Publication date: 2007-01-01